Trial Profile
Phase III Clinical Study on Taste Disorder by Z-103 -Double Blind Comparison Study on Patients with Zinc-Deficient and Idiopathic Taste Disorders -
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 May 2016
Price :
$35
*
At a glance
- Drugs Polaprezinc (Primary)
- Indications Taste disorders
- Focus Therapeutic Use
- Sponsors Zeria
- 19 May 2016 New trial record